Lancôme's Longevity Ingredient Came With an Equity Stake

At a Lancôme counter, the new Absolue M.D. story will arrive as five formulas arranged around one compact scientific noun: Mitopure. Japan's nationwide rollout is scheduled for September 4, 2026, after online and department store previews. Yet the ingredient's route to the counter did not begin inside Lancôme, and it did not move directly from a supplement capsule into a cream.

Timeline, the Swiss health science company behind Mitopure, launched its own facial skin care line on January 17, 2023. Its announcement described Mitopure as a highly pure form of Urolithin A and said three topical clinical studies supported that range. In other words, the cosmetic turn had already been made, in finished products, a year before L'Oréal became an investor.

In January 2024, BOLD, L'Oréal's strategic venture fund, acquired a minority stake in Timeline. The Japanese disclosure was unusually clear about the sequence: the investment could enable future collaboration with L'Oréal. Timeline's account adds that BOLD led the financing round. Nestlé Health Science, an investor since 2019, was also involved. The molecule therefore sits inside a layered business network, with a Swiss biotechnology owner, a nutrition backer, and a global cosmetics investor.

What Lancôme added

On February 19, 2026, Japan L'Oréal announced the Lancôme partnership with Timeline. The five-part Absolue M.D. line is the consumer result: Timeline supplies its patented ingredient and related research; Lancôme brings new finished formulas, prestige packaging, beauty advisers, and a retail system that can place the story at counters across Japan.

This is not the same as L'Oréal acquiring Timeline or inventing Urolithin A. The disclosed holding remains a minority one, and Timeline's parent company, Amazentis, is still identified as the ingredient owner. What changed is scale and framing. A molecule already sold in specialist supplements and skin care is now carried by Lancôme's name and distribution.

The ownership trail also sharpens how the product language should be read. The 98 or 98.5 percent figure used in launch materials describes the purity of the micronized Urolithin A ingredient, not its concentration in a jar. Japan L'Oréal's July announcement identifies Urolithin A as a skin-conditioning ingredient but does not state how much Mitopure each finished formula contains.

For readers assessing the biological skin age language, the useful next step is not to collapse every claim into one glossy surface. Ask whether a result belongs to the molecule, Timeline's earlier topical formulas, or the final Lancôme formula, then look for the participant count, duration, and comparator. The investment history does not invalidate the research. It tells you whose research, product, and commercial reach are meeting at the counter.

Sources: Japan L'Oréal launch announcement · Japan L'Oréal investment announcement · Timeline skin care announcement